BioSpace News Archive

ID Genomics, SPC today announced the completion of its first Pre-Submission meeting with the Food and Drug Administration for the CLoNeT E. coli Assay for Urinary Tract Infections (UTIs).

For the past twelve years, Canon Medical Systems USA, Inc. has partnered with AHRA: The Association for Medical Imaging Management in support of the Putting Patients First program, awarding grants dedicated to improving patient care and developing best imaging practices in the areas of CT, MR, Ultrasound, X-ray and Vascular.

The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time to discuss its second quarter 2019 financial and operating results.

Elekta (EKTA-B.ST) today announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has achieved regulatory certification from the Canadian Nuclear Safety Commission, clearing the technology for clinical use in Canada.

Predictive biomarkers can reduce unnecessary treatment and adverse effects unlike chemotherapy and targeted therapies which may cause toxic effects.

DionyMed Brands Inc. (“DionyMed” or “Company”) (CSE: DYME)(OTCQB:DYMEF), a multi-state cannabis brands platform, announced today that it has signed a definitive agreement to acquire select assets from MM Esperanza 2 LLC, doing business as “MMAC,” and MMAC’s 1.83 acre Los Angeles cannabis campus.

IDenta Corp. (OTCQB: IDTA) is a worldwide leader in the development of field Drug & Explosive detection kits and unique forensic products.

Several government bodies across the world are enforcing stringent regulations to tackle the adverse environmental effects of mercury emission.

Findings from a study published today in Lupus Science & Medicine™ provide an actionable framework to advance the lupus field, which has seen many failed clinical trials, variations in care and poor access to care worldwide.

Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has received a deficiency notice from Nasdaq indicating that, based upon a review of Motif Bio’s Market Value of Listed Securities (MVLS) for the last 30 consecutive business days,